Allogeneic bone marrow stem cell transplantation following CD34+immunomagnetic enrichment in patients with inherited metabolic storage diseases

T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell transplantation. This goal can be achieved either by selective removal of T cells or by positive selection of CD34 + cells. Large-scale preparations of purified CD34 + cells from bone marrow products have not been extensively described. We report our results with bone marrow C634 + cell enrichment using the CliniMACS system in eight children with IMSD. The median recovery of positively selected CD34 + cells was 46.2% with a purity of 9.5%, and a residual T cell content of 0.04 x 10(6). A median of 5.5 x 10(6)/kg of CD34+ cells was infused. All patients engrafted at a median time of 12 days and none of the patients developed GVHD. This method is technically feasible and can be successfully used to transplant children with IMSD.